Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage

Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action–based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial design options in this area, review examples...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacs, James, Tan, Aaron C., Hanks, Brent A., Wang, Xiaofei, Owzar, Kouros, Herndon, James E., Antonia, Scott J., Piantadosi, Steven, Khasraw, Mustafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738124/
https://www.ncbi.nlm.nih.gov/pubmed/34312214
http://dx.doi.org/10.1158/1078-0432.CCR-21-1593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738124/
https://www.ncbi.nlm.nih.gov/pubmed/34312214
http://dx.doi.org/10.1158/1078-0432.CCR-21-1593

Ejemplares similares